28 completed, 5 terminated, 5 unknown, 3 active not recruiting. 47 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Completed 28, Terminated 5, Unknown 5, Active not recruiting 3, Recruiting 3, Withdrawn 3 |
| Phase 1 | 7 | Completed 3, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors Everolimus 5 MG - Neuroendocrine Tumors, Progression | Phase 2 | Recruiting | AC Camargo Cancer Center | 100 | 2024-04-24 | 2024-06-25 |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) Lu-177-DOTATATE, Olaparib, Ga dotatate scanning - Gastroenteropancreatico Tumors, Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 56 | 2022-10-03 | 2026-10-16 |
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 36 | 2022-04-22 | 2026-03-19 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors Cabozantinib, Nivolumab - Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 111 | 2022-01-21 | 2026-07-28 |
| Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors Telotristat Ethyl Oral Tablet - Neuroendocrine Tumors | Phase 2 | Withdrawn | University of Chicago | 2022-01-01 | 2021-12-17 | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome | Phase 2 | Unknown | King's College Hospital NHS Trust | 20 | 2020-10-01 | 2020-08-04 |
| Cabozantinib and Nivolumab for Carcinoid Tumors Nivolumab, Cabozantinib - Carcinoid Tumor, Carcinoid Tumor of GI System | Phase 2 | Completed | Dana-Farber Cancer Institute | 19 | 2019-12-26 | 2025-01-31 |
| Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Nivolumab, Ipilimumab - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 9 | 2018-03-09 | 2024-01-09 |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Lanreotide, Y-90 microspheres - Neuroendocrine Tumors, Gastrointestinal Neoplasms | Phase 2 | Terminated | SCRI Development Innovations, LLC | 6 | 2017-07-28 | 2023-12-05 |
| A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Ramucirumab, Somatostatin Analog - Carcinoid Tumors | Phase 2 | Completed | Dana-Farber Cancer Institute | 43 | 2016-06-14 | 2025-02-19 |
| Personalized PRRT of Neuroendocrine Tumors 177Lu-Octreotate - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Active not recruiting | CHU de Quebec-Universite Laval | 275 | 2016-04-12 | 2024-08-21 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) pembrolizumab - Advanced Cancer, Anal Carcinoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 1609 | 2015-12-18 | 2025-09-22 |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors surufatinib - Tumors | Phase 1 / Phase 2 | Completed | Hutchmed | 130 | 2015-11-01 | 2024-07-10 |
| Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Ibrutinib - Carcinoid Tumors, Pancreatic NET | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2015-10-09 | 2020-09-11 |
| Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors 68Ga-DOTATOC PET/CT - Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Completed | Sue O'Dorisio | 122 | 2015-09-01 | 2020-12-21 |
| Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers Carfilzomib - Neuroendocrine Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 62 | 2015-07-15 | 2023-12-05 |
| Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study - Carcinoid Tumor, Metastatic Carcinoid Tumor | Phase 2 | Completed | Roswell Park Cancer Institute | 32 | 2015-05-15 | 2023-12-26 |
| Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Recombinant anti-tumor and anti-virus protein for injection (Novaferon) - Neuroendocrine Tumors | Phase 2 | Unknown | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 20 | 2015-05-01 | 2016-01-05 |
Showing 20 of 47. Sign in to see all of them.
Neuroendocrine Tumors (33) · Neoplasm Metastasis (9) · Adenoma, Islet Cell (8) · Carcinoma (5) · Carcinoma, Neuroendocrine (5) · Neoplasms (4) · Neuroblastoma (4) · Serotonin Syndrome (4) · Gastrinoma (3) · Paraganglioma (3) · Pheochromocytoma (3) · Vipoma (3) · Apudoma (2) · Colorectal Neoplasms (2)
Adenocarcinoma (47) · Neoplasms by Histologic Type (47) · Neoplasms, Germ Cell and Embryonal (47) · Neoplasms, Glandular and Epithelial (47) · Neoplasms, Nerve Tissue (47) · Neuroectodermal Tumors (47) · Neoplasms (43) · Carcinoma (42) · Neoplasms by Site (20) · Digestive System Diseases (16) · Digestive System Neoplasms (16) · Endocrine Gland Neoplasms (16) · Endocrine System Diseases (16) · Neuroendocrine Tumors (14) · Pancreatic Diseases (13)
Everolimus (4) · Nivolumab (3) · cabozantinib (3) · lanreotide (3) · lutetium Lu 177 dotatate (3) · Bevacizumab (2) · Erlotinib Hydrochloride (2) · Octreotide (2) · Sunitinib (2) · gallium Ga 68 dotatate (2) · ganitumab (2) · pasireotide (2) · (18F)GTP1 (1) · 177Lu-octreotate (1) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1)
Dana-Farber Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Novartis Pharmaceuticals (3) · SCRI Development Innovations, LLC (2) · Sue O'Dorisio (2) · University of California, San Francisco (2) · AC Camargo Cancer Center (1) · Amgen (1) · Arbutus Biopharma Corporation (1) · Boston Medical Center (1) · British Columbia Cancer Agency (1) · CASI pharmaceuticals, Inc. (1) · CHU de Quebec-Universite Laval (1) · Callisto Pharmaceuticals (1) · Columbia University (1)
United States (36) · Canada (3) · France (3) · Poland (3) · Brazil (2) · China (2) · Italy (2) · Spain (2) · Argentina (1) · Belgium (1) · Germany (1) · Mexico (1) · Netherlands (1) · Peru (1) · Sweden (1)
Jonathan Strosberg, M.D. (3) · David Spigel, M.D. (2) · Christine Hann, MD/PhD (1) · Ebrahim Delpassand, M.D. (1) · Emily K. Bergsland, MD (1) · Francois Benard, MD (1) · Frank I Lin, M.D. (1) · Gary Jacob, Ph.D. (1) · Jean-Mathieu Beauregard, MD,MSc,FRCPC (1) · Jennifer A Chan, MD MPH (1) · Jennifer Chan, MD (1) · Jennifer Chan, MD, MPH (1) · Jonathan Strosberg, MD (1)
PMID 23516312, PMID 25376618, PMID 26769865, PMID 28153957, PMID 29181270, PMID 30506283, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36395401, PMID 36748723, PMID 37074571, PMID 39500789, PMID 39834129, PMID 39979665, PMID 40121391, PMID 41920388
2015 (1)